Diabetes Duration and the Efficacy and Safety of Insulin Glargine Versus Comparator Treatment in Patients with Type 2 Diabetes Mellitus |
| |
| Institution: | 1. University of Colorado Denver, Aurora, Colorado;2. Sanofi US, Inc., Bridgewater, New Jersey;3. Medpace, Cincinnati, Ohio.;4. Scripps Clinic, La Jolla, California.;1. Department of Endocrinology, Charlie Norwood VA Medical Center;2. Section of Endocrinology Diabetes and Metabolism, Georgia Regents University;3. Department of Pathology, Charlie Norwood VA Medical Center;4. Department of Pathology, Georgia Regents University, Augusta, Georgia.;1. Sackler School of Medicine, Tel Aviv University, Israel;2. Unit of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel;3. Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel;4. Endocrinology and Metabolism Institute, Rabin Medical Center, Petah Tikva, Israel;5. Department of Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel Aviv University;6. Schneider’s Children’s Medical Center, Petah Tikva, Israel.;1. Department of Pediatrics;2. Department of Internal Medicine, Baystate Medical Center, Springfield, Massachusetts.;1. Department of General Surgery, Cleveland Clinic Foundation;2. Department of Anatomic Pathology, Cleveland Clinic Foundation;3. Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio;4. Department of Endocrine Surgery, Cleveland Clinic Foundation. |
| |
| Abstract: | ObjectiveTo evaluate the effect of diabetes duration on efficacy and safety in patients with type 2 diabetes mellitus (T2DM) using insulin glargine versus comparator (oral antidiabetic drugs OADs], dietary changes, or other insulins).MethodsData were pooled from randomized controlled clinical trials conducted in adults with T2DM with at least 24-week treatment with insulin glargine or a comparator, where predefined insulin titration algorithms were utilized to achieve fasting plasma glucose (FPG) concentrations of ≤ 100 mg/dL. Glycated hemoglobin A1C (A1C), FPG, and insulin dose and safety (hypoglycemia) outcomes were analyzed.ResultsNine studies were included in the analysis of 2,930 patients. Patients with shorter duration of diabetes were more likely to have greater reductions in A1C compared with those who had longer-duration disease (P < .0001). Disease duration did not affect change in FPG concentrations (P = .9017), but lower weight-adjusted insulin dose was correlated with longer-duration disease (P < .0001). Patients with longer-duration diabetes had increased risks of symptomatic hypoglycemia, confirmed hypoglycemia (self-monitored blood glucose < 50 mg/dL and < 70 mg/dL), and nocturnal hypoglycemia (all P < .001). No significant relationship was found between severe hypoglycemia and duration of diabetes. However, treatment with insulin glargine lowered A1C values more effectively than comparator treatments with fewer hypoglycemic episodes.ConclusionPatients with shorter-duration T2DM better achieved target A1C levels and had less hypoglycemia than those with longer disease duration. Insulin glargine was associated with reduced A1C and fewer hypoglycemic events than comparators, regardless of disease duration. (Endocr Pract. 2014;20:120-128) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
